A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors

Klaus Mross,H. Richly,Annette Frost,D. Scharr,B. Nokay,Ralph Graeser,Chooi Lee,James Hilbert,Rainer-George Goeldner,O. Fietz,M. E. Scheulen

A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors

2016

Klaus Mross
H. Richly
Annette Frost
D. Scharr
B. Nokay
Ralph Graeser
Chooi Lee
James Hilbert
Rainer-George Goeldner
O. Fietz
M. E. Scheulen

Purpose This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and antitumor activity of the Aurora B kinase inhibitor BI 811283 in patients with advanced solid tumors.

Keywords:

Mitosis Modulators
Aurora B kinase
Pharmacology
Apoptosis
Pharmacodynamics
Aurora Kinase B
Immunohistochemistry
Keratin 18
Medicine
Pharmacokinetics
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations